These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1175123)

  • 1. Prognostic factors in multiple myeloma.
    Alexanian R; Balcerzak S; Bonnet JD; Gehan EA; Haut A; Hewlett JS; Monto RW
    Cancer; 1975 Oct; 36(4):1192-201. PubMed ID: 1175123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unmaintained remissions in multiple myeloma.
    Alexanian R; Gehan E; Haut A; Saiki J; Weick J
    Blood; 1978 Jun; 51(6):1005-11. PubMed ID: 647110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remission maintenance therapy for multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of low-dose prednisone and melphalan in the treatment of poor-risk patients with multiple myeloma.
    Cuttner J; Wasserman LR; Martz G; Sonntag RW; Kyle RA; Silver RT; Spurr C; Harley JB; Wiernik PM; Cornwell GG; Falkson G; Glidewell O; Holland JF
    Med Pediatr Oncol; 1975; 1(3):207-16. PubMed ID: 1232529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors in multiple myeloma treated with prednisolone and sequential melphalan and ifosfamide: MIP combination chemotherapy.
    Adachi T; Asano K; Sezaki T; Takahashi I; Kimura I
    Acta Med Okayama; 1982 Feb; 36(1):39-47. PubMed ID: 7064732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
    Case DC; Lee DJ; Clarkson BD
    Am J Med; 1977 Dec; 63(6):897-903. PubMed ID: 605911
    [No Abstract]   [Full Text] [Related]  

  • 7. Bone healing in multiple myeloma with melphalan chemotherapy.
    Rodriguez LH; Finkelstein JB; Shullenberger CC; Alexanian R
    Ann Intern Med; 1972 Apr; 76(4):551-6. PubMed ID: 4640313
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognosis of myelomatosis on treatment with prednisone and cytostatics.
    Hansen OP; Jessen B; Videbaek A
    Scand J Haematol; 1973; 10(4):282-90. PubMed ID: 4764610
    [No Abstract]   [Full Text] [Related]  

  • 9. Correlation of abnormal immunoglobulin with clinical features of myeloma.
    Arch Intern Med; 1975 Jan; 135(1):46-52. PubMed ID: 1111470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroid therapy of multiple myeloma and macroglobulinemia.
    Hoogstraten B
    Med Clin North Am; 1973 Sep; 57(5):1321-30. PubMed ID: 4366516
    [No Abstract]   [Full Text] [Related]  

  • 11. The Effect of Suppressed Levels of Uninvolved Immunoglobulins on the Prognosis of Symptomatic Multiple Myeloma.
    Sarı M; Sarı S; Nalçacı M
    Turk J Haematol; 2017 Jun; 34(2):131-136. PubMed ID: 27795224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors and the effect of alkylating agents on survival in multiple myeloma. A review of 80 patients.
    Matzner Y; Benbassat J; Polliack A
    Isr J Med Sci; 1977 Aug; 13(8):797-807. PubMed ID: 408296
    [No Abstract]   [Full Text] [Related]  

  • 13. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients.
    Belch A; Shelley W; Bergsagel D; Wilson K; Klimo P; White D; Willan A
    Br J Cancer; 1988 Jan; 57(1):94-9. PubMed ID: 3279997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of bone marrow plasma cell infiltration in stage I multiple myeloma.
    Cavo M; Baccarani M; Gobbi M; Lipizer A; Tura S
    Br J Haematol; 1983 Dec; 55(4):683-90. PubMed ID: 6671088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prognostic index for multiple myeloma.
    Grignani G; Gobbi PG; Formisano R; Pieresca C; Ucci G; Brugnatelli S; Riccardi A; Ascari E
    Br J Cancer; 1996 May; 73(9):1101-7. PubMed ID: 8624271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of multiple myeloma.
    Waldenström J
    Br J Haematol; 1968 Sep; 15(3):217-20. PubMed ID: 5681477
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination therapy for multiple myeloma.
    Alexanian R; Salmon S; Bonnet J; Gehan E; Haut A; Weick J
    Cancer; 1977 Dec; 40(6):2765-71. PubMed ID: 589554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognosis in myelomatosis treated with prednisone and cytostatics].
    Hansen OP; Jessen B; Videbaek A
    Ugeskr Laeger; 1973 Jun; 135(23):1169-73. PubMed ID: 4757116
    [No Abstract]   [Full Text] [Related]  

  • 19. Acute leukemia in multiple myeloma.
    Gonzalez F; Trujillo JM; Alexanian R
    Ann Intern Med; 1977 Apr; 86(4):440-3. PubMed ID: 403840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of multiple myeloma.
    San Miguel JF; Bladé Creixenti J; García-Sanz R
    Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.